163 related articles for article (PubMed ID: 6810204)
1. Prolactin secretion in Parkinson disease.
Eisler T; Thorner MO; MacLeod RM; Kaiser DL; Calne DB
Neurology; 1981 Oct; 31(10):1356-9. PubMed ID: 6810204
[TBL] [Abstract][Full Text] [Related]
2. Function of dopamine receptors in Parkinson's disease: prolactin responses.
Laihinen A; Rinne UK
Neurology; 1986 Mar; 36(3):393-5. PubMed ID: 3081830
[TBL] [Abstract][Full Text] [Related]
3. Carbidopa plus L-dopa pretreatment inhibits the prolactin (PRL) response to thyrotropin-releasing hormone and thus cannot distinguish central from pituitary sites of prolactin stimulation.
Carlson HE
J Clin Endocrinol Metab; 1986 Jul; 63(1):249-51. PubMed ID: 3086358
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
Martinez-Campos A; Giovannini P; Parati E; Novelli A; Caraceni T; Müller EE
J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
[TBL] [Abstract][Full Text] [Related]
5. Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
Martinez-Campos A; Giovannini P; Novelli A; Cocchi D; Caraceni T; Müller EE
Acta Endocrinol (Copenh); 1982 Mar; 99(3):344-51. PubMed ID: 6803485
[TBL] [Abstract][Full Text] [Related]
6. Effect of levodopa on thyroid function and prolactin release. A study in patients with Parkinson's disease.
Lavin PJ; Gawel MJ; Das PK; Alaghband-Zadeh J; Rose FC
Arch Neurol; 1981 Dec; 38(12):759-60. PubMed ID: 6797388
[No Abstract] [Full Text] [Related]
7. [Patients with Parkinson disease: functional analysis of dopamine receptors by bromocriptine- thyrotropin-releasing hormone test].
Díaz F; Liberman C; Chariá P
Rev Med Chil; 1991 Mar; 119(3):252-7. PubMed ID: 1842116
[TBL] [Abstract][Full Text] [Related]
8. Dissociation of thyrotropin and prolactin responsiveness to thyrotropin releasing hormone stimulation in L-dopa treated parkinsonian patients.
Rabey JM; Vardi Y; Ravid R; Ayalon D
Horm Res; 1981; 15(2):78-87. PubMed ID: 6799381
[TBL] [Abstract][Full Text] [Related]
9. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
Ishibashi M; Yamaji T
J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
[TBL] [Abstract][Full Text] [Related]
10. Hypothalamic dopamine is required for salsolinol-induced prolactin secretion in goats.
Hashizume T; Watanabe R; Inaba Y; Sawai K; Fülöp F; Nagy GM
Anim Sci J; 2017 Oct; 88(10):1588-1594. PubMed ID: 28556305
[TBL] [Abstract][Full Text] [Related]
11. Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response.
Agnoli A; Baldassarre M; Ruggieri S; Falaschi P; Urso RD; Rocco A
J Neural Transm; 1981; 51(1-2):123-34. PubMed ID: 7264625
[TBL] [Abstract][Full Text] [Related]
12. The extracerebral dopamine antagonist domperidone block the suppressive effect of bromocriptine on prolactin and TSH secretion in man.
Svet-Moldavsky I; Svet-Moldavsky G; Zinzar S; Holland J; Vergara C; Arlin Z; Koziner B; Clarkson B
Biomedicine; 1981 Oct; 35(5):142-4. PubMed ID: 6797487
[TBL] [Abstract][Full Text] [Related]
13. Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery.
Barbarino A; De Marinis L; Anile C; Menini E; Merlini G; Maira G
Metabolism; 1982 Nov; 31(11):1100-4. PubMed ID: 6813636
[TBL] [Abstract][Full Text] [Related]
14. [Effect of dopaminergic pharmacological agents on thyrotropic hormone secretion by the hypophysis when stimulated with thyrotropin-releasing hormone].
Boiadzhieva N; Zakharieva B; Ovcharov R
Eksp Med Morfol; 1985; 24(1):29-32. PubMed ID: 3928331
[No Abstract] [Full Text] [Related]
15. Abnormal regulation of prolactin release in idiopathic Parkinson's disease.
Lawton NF; MacDermot J
J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1012-5. PubMed ID: 6777462
[TBL] [Abstract][Full Text] [Related]
16. Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy.
Vogel HP; Ketsche R
J Neurol; 1986 Jun; 233(3):149-52. PubMed ID: 3088217
[TBL] [Abstract][Full Text] [Related]
17. Effects of hypothalamic dopamine on growth hormone-releasing hormone-induced growth hormone secretion and thyrotropin-releasing hormone-induced prolactin secretion in goats.
Jin J; Hashizume T
Anim Sci J; 2015 Jun; 86(6):634-40. PubMed ID: 25442325
[TBL] [Abstract][Full Text] [Related]
18. Suppression of prolactin secretion by L-dopa in the stalk-sectioned rhesus monkey.
Diefenbach WP; Carmel PW; Frantz AG; Ferin M
J Clin Endocrinol Metab; 1976 Sep; 43(3):638-42. PubMed ID: 821963
[TBL] [Abstract][Full Text] [Related]
19. Cholinergic and dopaminergic mechanisms in Parkinson's disease after long term levodopa administration.
Yahr MD; Clough CG; Bergmann KJ
Lancet; 1982 Sep; 2(8300):709-10. PubMed ID: 6126641
[No Abstract] [Full Text] [Related]
20. Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Agnoli A; Ruggieri S; Baldassarre M; Rocco A; Del Roscio S; D'Urso R; Mearelli S; Falaschi P; Frajese G
Prog Clin Biol Res; 1980; 39():215-24. PubMed ID: 6773067
[No Abstract] [Full Text] [Related]
[Next] [New Search]
